Paul Maier V sold $3.0M of ETON
director at Eton Pharmaceuticals, Inc.. 50,000 shares at an average of $59.07, traded Aug 28, 2026, filed Aug 31, 2026.
Score components
- +15RoleDirector
- +25Trade size$3.0M at market
- +10Share of holdings soldSold 46% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-029308, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | MOption exercise Common Stock | +50,000 | $3.78 | $189k | 109,745 | 43 d ago |
| Aug 28, 2026 | SOpen-market sale Common Stock | -36,387 | $58.64 | $2.1M | 73,358 | 43 d ago |
| Aug 28, 2026 | SOpen-market sale Common Stock | -13,485 | $60.21 | $812k | 59,873 | 43 d ago |
| Aug 28, 2026 | SOpen-market sale Common Stock | -128 | $61.77 | $7,907 | 59,745 | 43 d ago |
| Aug 28, 2026 | MOption exercise Common Stock | +12,500 | $7.31 | $91k | 72,245 | 43 d ago |
| Aug 28, 2026 | MOption exercise Employee Stock Optionderivative | -50,000 | $0.00 | $0 | 0 | 43 d ago |
| Aug 28, 2026 | MOption exercise Employee Stock Optionderivative | +12,500 | $0.00 | $0 | 0 | 43 d ago |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $1.6M 25,000 shares | -40% | |
| 65Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $6.1M 100,000 shares | -9% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $4.8M 126,685 shares | -5% | |
| 45Moderate | ETONsell Eton Pharmaceuticals, Inc. | Jennifer McKie Adams director | $1.6M 50,000 shares | -100% | |
| 63Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.8M 120,000 shares | -13% | |
| 53Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $3.2M 100,000 shares | -147% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.